185 related articles for article (PubMed ID: 35835111)
1. Allosteric control of type I-A CRISPR-Cas3 complexes and establishment as effective nucleic acid detection and human genome editing tools.
Hu C; Ni D; Nam KH; Majumdar S; McLean J; Stahlberg H; Terns MP; Ke A
Mol Cell; 2022 Aug; 82(15):2754-2768.e5. PubMed ID: 35835111
[TBL] [Abstract][Full Text] [Related]
2. Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications.
Hu C; Myers MT; Zhou X; Hou Z; Lozen ML; Nam KH; Zhang Y; Ke A
Mol Cell; 2024 Feb; 84(3):463-475.e5. PubMed ID: 38242128
[TBL] [Abstract][Full Text] [Related]
3. A Tryptophan 'Gate' in the CRISPR-Cas3 Nuclease Controls ssDNA Entry into the Nuclease Site, That When Removed Results in Nuclease Hyperactivity.
He L; Matošević ZJ; Mitić D; Markulin D; Killelea T; Matković M; Bertoša B; Ivančić-Baće I; Bolt EL
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799639
[TBL] [Abstract][Full Text] [Related]
4. Structure basis for RNA-guided DNA degradation by Cascade and Cas3.
Xiao Y; Luo M; Dolan AE; Liao M; Ke A
Science; 2018 Jul; 361(6397):. PubMed ID: 29880725
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution and biochemical characterization of the RNA-guided helicase-nuclease protein Cas3 from type I-A CRISPR-Cas system.
Hu C; Ke A
Methods Enzymol; 2022; 673():405-424. PubMed ID: 35965014
[TBL] [Abstract][Full Text] [Related]
6. Structure and genome editing of type I-B CRISPR-Cas.
Lu M; Yu C; Zhang Y; Ju W; Ye Z; Hua C; Mao J; Hu C; Yang Z; Xiao Y
Nat Commun; 2024 May; 15(1):4126. PubMed ID: 38750051
[TBL] [Abstract][Full Text] [Related]
7. Introducing Large Genomic Deletions in Human Pluripotent Stem Cells Using CRISPR-Cas3.
Hou Z; Hu C; Ke A; Zhang Y
Curr Protoc; 2022 Feb; 2(2):e361. PubMed ID: 35129865
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights into DNA interference by CRISPR-associated nuclease-helicase Cas3.
Gong B; Shin M; Sun J; Jung CH; Bolt EL; van der Oost J; Kim JS
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16359-64. PubMed ID: 25368186
[TBL] [Abstract][Full Text] [Related]
9. CRISPR RNA-guided DNA cleavage by reconstituted Type I-A immune effector complexes.
Majumdar S; Terns MP
Extremophiles; 2019 Jan; 23(1):19-33. PubMed ID: 30284045
[TBL] [Abstract][Full Text] [Related]
10. Structure Basis for Directional R-loop Formation and Substrate Handover Mechanisms in Type I CRISPR-Cas System.
Xiao Y; Luo M; Hayes RP; Kim J; Ng S; Ding F; Liao M; Ke A
Cell; 2017 Jun; 170(1):48-60.e11. PubMed ID: 28666122
[TBL] [Abstract][Full Text] [Related]
11. CasA mediates Cas3-catalyzed target degradation during CRISPR RNA-guided interference.
Hochstrasser ML; Taylor DW; Bhat P; Guegler CK; Sternberg SH; Nogales E; Doudna JA
Proc Natl Acad Sci U S A; 2014 May; 111(18):6618-23. PubMed ID: 24748111
[TBL] [Abstract][Full Text] [Related]
12. Dynamic mechanisms of CRISPR interference by Escherichia coli CRISPR-Cas3.
Yoshimi K; Takeshita K; Kodera N; Shibumura S; Yamauchi Y; Omatsu M; Umeda K; Kunihiro Y; Yamamoto M; Mashimo T
Nat Commun; 2022 Aug; 13(1):4917. PubMed ID: 36042215
[TBL] [Abstract][Full Text] [Related]
13. Distinct Subcellular Localization of a Type I CRISPR Complex and the Cas3 Nuclease in Bacteria.
Govindarajan S; Borges A; Karambelkar S; Bondy-Denomy J
J Bacteriol; 2022 May; 204(5):e0010522. PubMed ID: 35389256
[TBL] [Abstract][Full Text] [Related]
14. Genome editing in mammalian cells using the CRISPR type I-D nuclease.
Osakabe K; Wada N; Murakami E; Miyashita N; Osakabe Y
Nucleic Acids Res; 2021 Jun; 49(11):6347-6363. PubMed ID: 34076237
[TBL] [Abstract][Full Text] [Related]
15. Repetitive DNA Reeling by the Cascade-Cas3 Complex in Nucleotide Unwinding Steps.
Loeff L; Brouns SJJ; Joo C
Mol Cell; 2018 May; 70(3):385-394.e3. PubMed ID: 29706536
[TBL] [Abstract][Full Text] [Related]
16. Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems.
Tan R; Krueger RK; Gramelspacher MJ; Zhou X; Xiao Y; Ke A; Hou Z; Zhang Y
Mol Cell; 2022 Feb; 82(4):852-867.e5. PubMed ID: 35051351
[TBL] [Abstract][Full Text] [Related]
17. Introducing a Spectrum of Long-Range Genomic Deletions in Human Embryonic Stem Cells Using Type I CRISPR-Cas.
Dolan AE; Hou Z; Xiao Y; Gramelspacher MJ; Heo J; Howden SE; Freddolino PL; Ke A; Zhang Y
Mol Cell; 2019 Jun; 74(5):936-950.e5. PubMed ID: 30975459
[TBL] [Abstract][Full Text] [Related]
18. Structure of the miniature type V-F CRISPR-Cas effector enzyme.
Takeda SN; Nakagawa R; Okazaki S; Hirano H; Kobayashi K; Kusakizako T; Nishizawa T; Yamashita K; Nishimasu H; Nureki O
Mol Cell; 2021 Feb; 81(3):558-570.e3. PubMed ID: 33333018
[TBL] [Abstract][Full Text] [Related]
19. Target DNA recognition and cleavage by a reconstituted Type I-G CRISPR-Cas immune effector complex.
Majumdar S; Ligon M; Skinner WC; Terns RM; Terns MP
Extremophiles; 2017 Jan; 21(1):95-107. PubMed ID: 27582008
[TBL] [Abstract][Full Text] [Related]
20. DNA targeting by the type I-G and type I-A CRISPR-Cas systems of Pyrococcus furiosus.
Elmore J; Deighan T; Westpheling J; Terns RM; Terns MP
Nucleic Acids Res; 2015 Dec; 43(21):10353-63. PubMed ID: 26519471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
